Clinical Trials—Multiple Treatments, Multiple End Points, and Multiple Lessons
- 21 May 2003
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (19) , 2575-2577
- https://doi.org/10.1001/jama.289.19.2575
Abstract
In 1986, the GISSI group1 published a report of a large randomized clinical trial demonstrating that intravenous streptokinase reduces the risk of death among patients with acute myocardial infarction. The design of the trial was simple, as was the published report. There was one treatment, intravenous streptokinase, whereas the control group received no streptokinase. There was no blinding and no placebo. The end point of interest was death from any cause during hospitalization.Keywords
This publication has 16 references indexed in Scilit:
- Outcome of Elderly Patients With Chronic Symptomatic Coronary Artery Disease With an Invasive vs Optimized Medical Treatment StrategyJAMA, 2003
- Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary InterventionJAMA, 2003
- Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trialAmerican Heart Journal, 2002
- Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyTrials, 2001
- Accuracy of Death Certificates for Coding Coronary Heart Disease as the Cause of DeathAnnals of Internal Medicine, 1998
- Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non–q-wave myocardial infarction (a thrombin inhibition in myocardial ischemia [trim] substudy)The American Journal of Cardiology, 1998
- Dead is dead—artificial definitions are no substituteThe Lancet, 1997
- Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIATThe Lancet, 1997
- Perspectives on Large-Scale Cardiovascular Clinical Trials for the New MillenniumCirculation, 1997
- The Continuing Unethical Use of Placebo ControlsNew England Journal of Medicine, 1994